COMPANY

On the road to early cancer prevention,
accompanied by Marker X

ABOUT COMPANY

Have you ever considered how similar your blood is to that of cancer patients?

Simply provide a 3 ml blood sample, and receive your report within 10 working days.

Our core value is based on providing the best screening technology for cancer prevention, accompanying medical teams in continuous advancement, and enabling more lives to create infinite value.

Marker X is a cancer detection company that utilizes advanced technology to examine the protein composition in the blood for cancer risk. Our proprietary 'multi-index algorithm' is a pioneer in this field, effectively assisting the public in early detection and treatment of various types of cancer.

The testing method does not require surgery or endoscopic examination; a simple blood draw is all that's needed. Our testing method is more discerning, quicker and more precise than traditional methods.

In the future, we will expand our testing technology to screening for other chronic diseases, such as cardiovascular diseases. Additionally, we are also developing companion diagnostics related to medications, assisting doctors and patients in making more comprehensive and personalized assessments before medication use. Our partners include major teaching hospitals, diagnostic technology units, health examination centers, and research units.

OUR STORY

Precise cancer screening begins with Marker X.

Advanced testing technologies assist clients in effectively preventing cancer risks, while our professional laboratory team enhances medical and research productivity.

2020 - Company Establishment

The entrepreneurial team ventured out of the campus and laboratory, boldly entering the business jungle, promoting the latest cancer screening technologies.

2021 - Establishment of Professional Laboratory

During the process of developing proprietary products, we deeply understood the importance of teamwork. Therefore, we established a professional laboratory and expanded recruitment to conduct research and development on new technologies and products.

2022 - Launch of Early Multi-Cancer Screening Services

The company has become a biotech startup, with business covering areas such as cancer screening and proteomic analysis services. We have developed novel cancer protein markers for breast cancer, lung cancer, colorectal cancer, and esophageal cancer. By launching early multi-cancer screening services, we create greater value for our clients and shareholders.

2023 - Initiation of Prospective clinical validation

We promote Laboratory Developed Tests (LDTs) developed in-house, which can provide customized testing services tailored to the specific needs of clients. We collaborate with medical centers to conduct forward-looking sampling verification, earning recognition from domain experts.

TEAM

  • Executive Chairman

    Cheng-Hsien Hsu

    My journey as an entrepreneur began with the painful experience of my wife's passing due to cancer. This became the origin and driving force behind my involvement in Precision Biomedicine.

    My wife and I retired from our teaching positions after turning fifty, expecting to enjoy the second half of life together. However, shortly thereafter, my wife was diagnosed with stage III lung adenocarcinoma, and our lives underwent significant changes.

    In shock and grief, our family made every effort to adjust to the new rhythm of life. My daughters and I accompanied my wife in and out of hospitals for various examinations and treatments.

    Due to our Christian faith, we found peace and hope in our hearts. Despite suffering, my wife endured pain and difficulties, often experiencing the real presence of God, comforting us, praying, and encouraging our family.

    However, during the later stages of recurrence, we felt exhausted and saddened by my wife's rapid physical deterioration and the side effects of treatment. Eventually, she passed away before reaching the age of sixty, returning to her heavenly home.

    Although death is inevitable for everyone, my wife's rapid passing due to cancer cells' attack left me deeply saddened and regretful. This experience prompted me to consider if there was a chance to help other families detect cancer symptoms early and cure them promptly, allowing us to spend more time with our loved ones, expressing love, gratitude, and farewells.

    As a result, I embarked on a long journey to promote more widespread early cancer screening, hoping to assist more people, especially those unfortunate families facing the challenge of cancer like mine. By advocating for early cancer screening, we can strive for more time, initiate timely treatment measures, and ultimately improve the survival rate and quality of life for cancer patients.

    Precision Biomedicine has achieved some milestones on this journey, but this is not the end. We will continue our efforts to provide early cancer screening to more people in need until cancer is no longer the leading cause of death among the population.

    Former Professor of Biochemistry, National Taipei University of Nursing and Health Sciences
    Executive Chairman

    董事長 許承先

PROFESSIONAL TEAM

NEXT

SERVICE